RXi Pharmaceuticals Corp
SEC CIK 1533040 · RXII · last insider filing 2026-06-29
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Bitterman Robert J | Director · President & CEO | filed 2013 - 2026 |
| Bradford Patricia A | Director | filed 2022 - 2026 |
| Lockshin Curtis | Director | filed 2013 - 2026 |
| Deming David H | Director | filed 2025 - 2026 |
| Freeman Jonathan E | Director | filed 2017 - 2026 |
| Ferrara Robert L | Director | filed 2019 - 2025 |
| Cauwenbergh Geert | Director · President and CEO | filed 2013 - 2023 |
| Dispersyn Gerrit | Director · President & COO | filed 2017 - 2022 |
| Dorman H. Paul | Director | filed 2013 - 2022 |
| Brownlie Keith L | Director | filed 2013 - 2019 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Carson Lisa Cabott | VP, Finance and Administration | filed 2025 - 2026 |
| Infarinato Robert M. | VP, Chief Financial Officer | filed 2024 - 2024 |
| Kontulis Caitlin | Secretary and Controller | filed 2013 - 2024 |
| Barrett John A | Chief Development Officer | filed 2019 - 2019 |
| Eliseev Alexey | Chief Business Officer | filed 2017 - 2017 |
| Pavco Pamela | Chief Development Officer | filed 2013 - 2017 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.